MaxCyte Inc. | Mutual Funds
Mutual Funds that own MaxCyte Inc.
Legal & General UK Alpha Trust
3,500,000
9.89%
0
5.36%
07/31/2018
Unicorn AIM VCT Plc
2,142,857
6.05%
0
2.62%
08/31/2018
Marlborough UK Micro Cap Growth Fund
1,817,253
5.13%
3
0.36%
03/29/2018
1,792,857
5.05%
0
0.48%
06/30/2018
Jupiter UK Smaller Companies Fund
325,000
0.92%
0
0.25%
02/28/2018
Hargreave Hale AIM VCT 1 Plc
288,045
0.81%
46,564
0.92%
09/30/2017
Hargreave Hale AIM VCT 2 Plc
198,723
0.56%
-22,518
0.93%
02/28/2017
Amati VCT 2 Plc
148,928
0.42%
-2,499
0.53%
01/31/2018
Octopus AIM VCT 2 Plc
125,879
0.36%
125,879
0.39%
05/31/2017
| Address |
22 Firstfield Road
Gaithersburg Maryland 20878
United States
|
|
Employees
|
- |
| Website |
http://www.maxcyte.com |
| Updated |
07/08/2019 |
| MaxCyte, Inc. enages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include MaxCyte STX, MaxCyte VLX, and MaxCyte GT. |
